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Immunoprecipitation and subsequent mass spectrometry analysis of the cellular proteins from cells ex-
pressing the vesicular stomatitis virus (VSV) P protein identified the poly(C) binding protein 2 (PCBP2) as one
of the P protein-interacting proteins. To investigate the role of PCBP2 in the viral life cycle, we examined the
effects of depletion or overexpression of this protein on VSV growth. Small interfering RNA-mediated silencing
of PCBP2 promoted VSV replication. Conversely, overexpression of PCBP2 in transfected cells suppressed VSV
growth. Further studies revealed that PCBP2 negatively regulates overall viral mRNA accumulation and
subsequent genome replication. Coimmunoprecipitation and immunofluorescence microscopic studies showed
that PCBP2 interacts and colocalizes with VSV P protein in virus-infected cells. The P-PCBP2 interaction did
not result in reduced levels of protein complex formation with the viral N and L proteins, nor did it induce
degradation of the P protein. In addition, PCBP1, another member of the poly(C) binding protein family with
homology to PCBP2, was also found to interact with the P protein and inhibit the viral mRNA synthesis at the
level of primary transcription without affecting secondary transcription or genome replication. The inhibitory
effects of PCBP1 on VSV replication were less pronounced than those of PCBP2. Overall, the results presented
here suggest that cellular PCBP2 and PCBP1 antagonize VSV growth by affecting viral gene expression and
highlight the importance of these two cellular proteins in restricting virus infections.
Vesicular stomatitis virus (VSV) is an enveloped RNA virus
in the family Rhabdoviridae. The negative-sense RNA genome
of VSV is 11,161 nucleotides in length and encodes 5 proteins:
the nucleocapsid protein (N), the phosphoprotein (P), the ma-
trix (M), the glycoprotein (G), and the large protein (L). Inside
the virion, the viral genome is tightly encapsidated with the N
protein to form the ribonucleocapsid complex (RNP or NC)
with which the viral RNA-dependent RNA polymerase
(RdRp) complex of P-L proteins (41) is associated. The G
protein forms spikes on the surface of the VSV virion and
mediates virus attachment as well as entry by clathrin-medi-
ated endocytosis. Based on the low-pH environment of the
endosome, the VSV G protein mediates fusion of the viral
envelope with the endosomal membrane, releasing the viral
RNP into the cytoplasm of the infected cell. Once inside the
cytosol, the RNP undergoes primary transcription by the asso-
ciated RdRp activity of the L protein along with its cofactor P
protein. Translation of the transcripts by the cellular transla-
tion machinery generates viral proteins, which are used for
further steps in the infection process, including genome repli-
cation, secondary transcription, assembly, and budding (53).
The viral P is a multifunctional protein that modulates the
association of viral replicative proteins and is indispensable for
viral growth. It is required for viral genome transcription and
replication (18) and also plays a role in packaging and assem-
bly of infectious VSV (19). Phosphorylation at different sites
within the protein appears to regulate its activity in transcrip-
tion and replication (18, 35, 49). Based on structural studies of
fragments of this protein (22, 23) and many functional studies
in the past, three domains have been recently proposed (48).
The carboxy-terminal domain (PCTD), spanning residues from
approximately 183 to 265, interacts with the N protein and is
required for replication (32). The amino-terminal domain
(PNTD), spanning residues 1 to 106, likely encodes critical
determinants of transcription activity and the L protein bind-
ing activity (20). The central domain (PCD) of the molecule,
spanning residues 107 to 177, is involved in the oligomerization
of the protein (22). Oligomerization of the P protein is crucial
for its association with the L protein and its function as a
cofactor in enzymatic activities of the viral RdRp.
Because of the multifunctional nature of the P protein, it is
likely that it interacts with many cellular proteins in virus-
infected cells. Studies have shown that the P protein is phos-
phorylated by cellular casein kinase II for its activity in viral
RNA synthesis and it also associates with c-src (3). The P
protein of rabies virus (another member of the family Rhab-
doviridae) interacts with dynein light chain LC8 (52), and this
interaction is suggested to be required for viral genome tran-
scription and replication in vivo and in vitro (56). Therefore,
identification of the cellular proteins that interact with the
VSV P protein and understanding how these interactions mod-
ulate P protein functions will provide a better understanding of
the involvement of the cellular and the viral proteins in the
replicative cycle of VSV. Apart from participating in genome
replication and transcription, viral replication proteins are also
involved in regulating the host cell response to virus infection.
In this study, we have used immunoprecipitation (IP) and
mass spectrometry (MS) analysis to identify the cellular pro-
teins that interact with the P protein. Our results reveal that
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among the many proteins identified by this method, the cellu-
lar poly(C) binding protein 2 (PCBP2) was consistently de-
tected in several repeat experiments. PCBP2, along with its
closely related isoform PCBP1 (which was also detected in our
studies), belongs to a family of nucleic acid binding proteins
with high affinity for binding to homopolymeric nucleic acids
(15). Our studies reported here show that depletion of
PCBP2 enhances VSV replication, whereas overexpression
of PCBP2 in plasmid-transfected cells inhibits virus replica-
tion. PCBP2 was further shown to negatively regulate the
levels of viral mRNA and subsequent genome replication
without adversely affecting the viral entry and uncoating
steps or virus budding. Interestingly, PCBP1 inhibited VSV
primary mRNA transcription without affecting secondary
transcription or viral genome replication. The P-PCBP2 in-
teraction did not hinder the normal association of P with the
N or the L protein or the homo-oligomerization of P mol-
ecules. Additionally, we have shown that the P protein is
ubiquitinated, and its degradation is dependent on the pro-
teasome pathway. However, the interaction of PCBP2 with
the P protein does not lead to the degradation of this viral
protein.
MATERIALS AND METHODS
Cell culture and reagents. Monolayer cultures of HeLa and HEK293 cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and the antibiotics penicillin (100
units/ml), kanamycin (20 units/ml), and streptomycin (20 units/ml) (PKS). Baby
hamster kidney (BHK-21) cells were maintained as described earlier (16). The
NPeGFPL stable cell line (47) derived from 293 cells was maintained as de-
scribed before (47) in the presence of 1 mg/ml G418. Cycloheximide, MG132,
and protease inhibitor cocktail were obtained from Sigma-Aldrich and used at
concentrations of 100 g/ml, 2 to 30 M, and 1, respectively.
Viruses, VSV DI particles, and nucleocapsid preparation. Recombinant vac-
cinia virus vTF7-3 (25) was prepared and titrated in BHK-21 cells as described
before (47). Stocks of VSV, VSV-eGFP, and VSV-PeGFP were prepared and
titrated as described earlier (17, 18). Defective interfering T particles (DI-T) (39)
of wild-type (wt) VSV were prepared and stored at 80°C in small aliquots until
use. For generating VSV-PeGFP-G virus, the G protein open reading frame
from pVSV-PeGFP (17) was removed by restriction digestion of the full-length
viral cDNA-carrying plasmid followed by religation. VSV-PeGFP-G virus was
recovered using VSV rescue methods (18) in the presence of G protein expressed
from a transfected plasmid under T7 RNA polymerase promoter. The VSV-
PeGFP-G virus was amplified by passaging the transfected cell culture super-
natants in cells expressing the G protein from a plasmid under the cytomegalo-
virus (CMV) promoter (pHyg-G, in which the entire coding region of the G
protein of VSV is cloned in place of the HygeGFP fusion protein in the
pHygeGFP vector from Clontech). The titration of VSV-PeGFP-G was per-
formed on VSV G-expressing BHK-21 cells and by determining the number of
fluorescent foci of infection. The viral NC from VSV-PeGFP was prepared with
modification to the protocol described before (21). Briefly, purified VSV-PeGFP
virus pellet was resuspended in nucleocapsid generation buffer (10 mM Tris-HCl,
pH 8.0; 0.4 M NaCl; 1.85% Triton X; 5% glycerol; 0.6 mM dithiothreitol) and
incubated on ice for 2 h with intermittent mixing. The sample was then centri-
fuged at 32,000 rpm for 3 h to pellet the NC. The pelleted nucleocapsid was then
resuspended in resuspension buffer (5% glycerol and 10 mM Tris-HCl, pH 8.0),
aliquoted, and frozen at 80°C until use.
Antibodies. Anti-M (23H12) and anti-N (10G4) monoclonal antibodies were
kindly provided by D. Lyles (9). Mouse anti-VSV (Indiana serotype) polyclonal
antibody and rabbit anti-P polyclonal antibody have been described before (19).
Antibodies against actin (sc-47778), PCBP1 (sc-16504), PCBP2 (sc-30725), ubiq-
uitin (sc-9133), and green fluorescent protein (GFP; sc-9996) were purchased
from Santa Cruz Biotechnology Inc. Antihemagglutinin (anti-HA) monoclonal
antibody HA-7 (H3663) and the polyclonal antibody (H6908), anti-Flag mono-
clonal antibody M2 (F3165) and the polyclonal antibody (F7425), goat anti-
rabbit immunoglobulin (IgG)–horseradish peroxidase (A6154) conjugate, goat
anti-mouse IgG–horseradish peroxidase (A4416) conjugate, and rabbit anti-goat
IgG–horseradish peroxidase (A4174) conjugate were obtained from Sigma-Al-
drich. Alexa Fluor 488 goat anti-rabbit (A11034) and Alexa Fluor 594 goat
anti-mouse IgG (A11032) were purchased from Invitrogen.
Plasmid constructs. pTKRL (Promega) and pISG56-luc plasmids have been
described before (7). HA-ubiquitin was expressed from the plasmid pMT123-
HA-ubiquitin, which was described previously (59). VSV P with a Flag tag at the
amino (N) terminus was cloned into the pHygeGFP vector. Coding sequences of
PCBP1 (NM_006196.3) and PCBP2 (NM_031989.4) were amplified using total
RNA recovered from HEK293 cells by using a LongAmp kit (New England
BioLabs). The reverse transcription-PCRs (RT-PCRs) for PCBP1 amplification
were performed using the forward primer NheI-HA-KpnI-PCBP1F containing
two restriction sites flanking the sequence for the HA epitope tag (shown in
italics) and the reverse primer EcoRI-PCBP1R (Table 1). The PCR product was
digested with NheI and EcoRI and cloned in the pcDNA3.1()Neo vector
(Invitrogen) digested with the same enzymes, and the plasmid was named
pcDHA-PCBP1. PCBP2 was amplified similarly with primers KpnI-PCBP2F and
EcoRI-PCBP2R (Table 1). The PCR product was digested with KpnI and
EcoRI. These two enzymes were also used to remove the PCBP1-carrying frag-
ment from the pcDHA-PCBP1 plasmid to generate a linear vector to clone the
PCBP2-carrying DNA fragment. This plasmid, pcDHA-PCBP2, carries PCBP2
with an HA tag at its N terminus. The entire sequences of the genes in these
plasmids were confirmed by nucleotide sequencing. These HA epitope-tagged
proteins could be expressed by both CMV and T7 promoter-driven expression
systems.
siRNA-mediated silencing. For depletion of PCBP1 and PCBP2 in HeLa as
well as in HEK293 cells, nontargeting (NT) control small interfering RNA
(siRNA) or siRNAs (pool of four different siRNAs) targeting PCBP1 or PCBP2
(Dharmacon catalog numbers M-012243-01-0005 and M-012002-01-0005, re-
spectively) were transfected at a final concentration of 10 nM (except where
indicated otherwise) following the protocol of reverse transfection with Lipo-
fectamine RNAiMax (Invitrogen) as recommended by the manufacturer. At 24 h
posttransfection (hpt), the transfection mix was replaced with DMEM containing
10% FBS and PKS and the cells were incubated further for 40 to 48 h to allow
knockdown of the gene.
Plasmid DNA and RNP transfection. Transfection of plasmids was performed
using Lipofectamine2000 (Invitrogen) as per the manufacturer’s instructions and
as described previously (2). At 4 hpt, the transfection mix was replaced with
complete growth medium and incubated for 40 to 44 h before being used for
TABLE 1. Primers used in this study
Primer name Primer sequence (5–3)a Use
NheI-HA-KpnI-PCBP1F GCCGCTAGCATGTACCCATACGATGTTCCAG
ATTACGCTGGTACCGATGCCGGTGTGACT
GAAAG
Amplification of PCBP1 with HA tag coding sequence
at 5 end
EcoRI-PCBP1R ATATGAATTCCTAGCTGCACCCCATGCC
KpnI-PCBP2F ATATGGTACCGACACCGGTGTGATTGAAGG Amplification of PCBP2
EcoRI-PCBP2R ATATGAATTCCTAGCTGCTCCCCATGCC
N-For ATGTCTGTTACAGTCAAGAG Amplification of fragment of VSV N mRNA
N-Rev CTGGAAGACCGTGTTCTC
P-For ATTATGAAGGAGCGCCAG Amplification of 3 end of P gene, P-M gene junction,
and 5 end of M gene in VSV antigenomeM-Rev GTGTAGACTCATACAAGAC
a Underlined portions of sequences indicate restriction enzyme sites; the portion in italics shows the sequence for the HA epitope tag.
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assays. Transfections of viral RNPs were also performed using the same proce-
dure as used for plamsid transfection.
Co-IP and MS. Cell monolayers were lysed in radioimmunoprecipitation assay
(RIPA) buffer without SDS (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% Triton
X-100, 1% sodium deoxycholate, and 1 protease inhibitor cocktail) and sub-
jected to coimmunoprecipitation (co-IP) following the procedure described pre-
viously (16). For MS analysis, the immunoprecipitated proteins were separated
on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels, the proteins were
stained using the silver staining method following a published protocol (11), and
the selected bands were excised from the stained gel for liquid chromatogra-
phy-MS analysis.
WB. Protein samples were separated by SDS-PAGE and transferred onto
polyvinylidene difluoride (PVDF) membranes. Membranes were soaked in
blocking buffer (phosphate-buffered saline [PBS] containing 5% nonfat dry milk
and 0.05% Tween 20) for 1 h and then probed with specific antibodies as
indicated below in each figure. Proteins were revealed by horseradish peroxidase-
labeled secondary antibody and visualized with an enhanced chemiluminescence
detection system (Pierce) following the manufacturer’s recommendations. Quan-
titative levels of protein expression were determined by scanning of Western
blotting (WB) data using Quantity-One software (Bio-Rad).
Semiquantitative RT-PCR. Total RNA from infected cells was extracted with
TRIzol (Invitrogen). For quantitation of viral mRNAs, first-strand cDNA was
synthesized using total RNA and oligo(dT) primer (Roche) followed by PCR
amplification of VSV N mRNA with specific primers (Table 1). For an internal
control, oligo(dT)-derived cDNA was used to amplify ribosomal protein L32
mRNA by using specific primers (Table 1) as described before (7). For quanti-
tation of full-length antigenome (replication product), total RNA was used to
synthesize cDNA with a reverse primer (Table 1) which binds to the antigenome
of VSV at sequences corresponding to the N terminus of M protein. The cDNA
was then used in PCR using the same reverse primer and a forward primer
(Table 1) that bound to the sequences corresponding to the C terminus of P
protein. The total RNA was also used to generate L32 PCR product (described
above) as an internal loading control for the amount of RNA used in the assays.
PCR cycling conditions used were 30 s at 94°C, 30 s at 54°C, and 40 s at 72°C for
25 cycles (protein-depleted cells) or 35 cycles (protein-overexpressing cells).
Virus infection and titration. Virus infection in each experiment was per-
formed at a multiplicity of infection (MOI) of 1 or 0.01 PFU per cell, except
where indicated otherwise, and the titers were determined in BHK-21 or HeLa
cells by plaque assay.
Immunofluorescence. HeLa cells grown on glass coverslips were transfected
with a vector encoding HA sequences alone (EV) or HA-PCBP2 or HA-PCBP1
protein-expressing plasmids. At 48 hpt, cells were infected with wt VSV at an
MOI of 1 for 3 h, followed by fixation with methanol-acetone (1:1) for 15 min at
30°C. After washing the cells with PBS twice, cells were stained with mouse
anti-HA monoclonal antibody and rabbit anti-P polyclonal antibody. Cells were
subsequently stained with Alexa Flour 594 goat anti-mouse IgG and Alexa Flour
488 goat anti-rabbit IgG. Images were obtained with an Olympus FV500/IX81
inverted laser scanning confocal microscope.
Statistical analyses. Statistical analyses were performed using the MIXED
procedure (SAS Institute Inc., Cary, NC). The statistical modeling included
treatment as a fixed effect. Data are presented as means  standard errors of
means. A P value of 0.05 was considered statistically significant.
RESULTS
Identification of cellular proteins that interact with VSV P
protein by IP and MS analysis. In an attempt to identify and
characterize cellular factors that interact with VSV P protein
and are involved in the VSV life cycle, we employed an IP
assay with lysates of cells expressing the VSV P protein, fol-
lowed by identification of the cellular proteins using MS anal-
ysis. The plasmid carrying the amino-terminal Flag-tagged P
protein (Flag-P), which is functional in viral genome transcrip-
tion and replication (unpublished data), or a vector encoding
only the Flag sequences (EV) was transfected into 293T cells.
IP of cell extracts was performed with anti-Flag antibody. The
immunoprecipitated proteins were separated by SDS-PAGE,
and the protein bands were detected by silver staining. Several
protein bands (identified by asterisks in Fig. 1) based on in-
creased or decreased intensity were observed in the Flag-P-
overexpressing lane compared to the EV lane. MS analysis of
some of these bands identified many cellular proteins, and only
those protein candidates that had at least two peptides (with
individual MASCOT scores of 	35) and that represented at
least 4% coverage of the corresponding full-length proteins are
shown on the right side of Fig. 1. For the purpose of confirming
the identity of the P protein, when we analyzed the presump-
tive P protein band by MS, we detected other cellular proteins,
including PCBP1 (also known as hnRNP E1) and PCBP2
(hnRNP E2), in addition to the VSV P protein. Besides PCBP1
and PCBP2, other cellular proteins were also identified (Fig.
1), and several of these proteins have been reconfirmed to
interact with the P protein. Many of these proteins are gener-
ally involved in cellular RNA metabolism and protein modifi-
cation processes (34, 36, 42). In this study, we focused on
examining the role of PCBP2 and PCBP1 in the VSV life cycle.
Both PCBP2 and PCBP1 interact and colocalize with VSV P
protein. To ascertain whether detection of PCBP2 in the
IP-MS analysis was due to specific interaction with the viral P
protein or was simply nonspecific binding with the antibody, we
examined interaction between PCBP2 and P proteins in trans-
FIG. 1. Identification of interacting partners of VSV P protein.
Flag-P carrying plasmid (5 g) or empty vector (EV; 5 g) were
transfected into 293T cells. At 48 hpt, cells were harvested for IP using
anti-Flag monoclonal antibody-conjugated beads for 12 h, followed by
separation of the proteins by 10% SDS-PAGE and silver staining.
Molecular mass markers (in kDa) are separated in lane M. The protein
bands identified by asterisks to the right of lanes were excised from the
gel and subjected to MS analysis. Proteins identified from MS analysis
of the bands are shown. ATAD3A, ATPase family AAA domain-
containing protein 3A; DDX5, RNA helicase p68; EMAP2, endothe-
lial-monocyte activating polypeptide II; hnRNP M4, heterogeneous
nuclear ribonucleoprotein M4; HSPA8, heat shock 70-kDa protein 8;
HSPA9, heat shock 70-kDa protein 9; HSP70, heat shock protein 70;
MEP50, methylosome protein 50; PRMT5, protein arginine N-meth-
yltransferase 5; NXF1, nuclear RNA export factor 1 (also known as
TAP); TRAP1, tumor necrosis factor type 1 receptor-associated pro-
tein.
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fected cells. Plasmids carrying HA-tagged PCBP2 (HA-
PCBP2) and Flag-tagged P (Flag-P) proteins were cotrans-
fected into 293T cells, immunoprecipitated with anti-Flag or
anti-HA antibody, resolved by SDS-PAGE, and then immuno-
blotted with anti-HA or anti-Flag antibody. The results (Fig.
2A) demonstrated a specific interaction when these two pro-
teins were coexpressed. Since the functions of PCBP2 are
known to be modulated by its interaction with RNA (12, 46),
we examined if the PCBP2-P interaction is mediated through
RNA. When the cell extracts were treated with ribonucleases
prior to IP, the PCBP2-P interaction was still detected at levels
similar to those without RNase treatment. The results showed
that PCBP2 interacts with the P protein and that this interac-
tion is independent of RNA.
In the family of PCBPs that contain 3 KH domains, the
human PCBP1 protein shares 89% amino acid sequence iden-
tity with PCBP2 protein and is slightly smaller (10 amino acids)
(58). This protein was also identified in the IP-MS analysis as
another P-interacting protein. Therefore, we investigated if P
protein also interacts with PCBP1 in transfected cells. To this
end, we coexpressed HA epitope-tagged PCBP1 (HA-PCBP1)
together with Flag-P in 293T cells. Interaction of P with these
proteins was examined as described above. The results (Fig.
2B) showed that the P protein also interacts with PCBP1 when
ectopically expressed in transfected cells.
Since VSV infection results in redistribution of hnRNP A1,
K, and C1/C2 proteins in the cytoplasm in the infected cells
(51), we investigated if the interaction of P with PCBP2 or
PCBP1 affects their intracellular distribution. Consistent with a
previous study (15), we found that in cells expressing HA-
PCBP2 or HA-PCBP1, these proteins were found to be dis-
tributed throughout the cells. The PCBP1 was predominantly
localized in the nucleus (Fig. 2C, panel vi), whereas PCBP2
was localized in both the nucleus and the cytoplasm (Fig. 2C,
panel ii), consistent with their association with RNA-process-
ing centers (12). In cells infected with VSV, the intracellular
FIG. 2. VSV P protein interacts and colocalizes with PCBP2 and PCBP1. (A) P-PCBP2 interaction. Two micrograms of each of the plasmids
carrying Flag-P and HA-PCBP2 was cotransfected into 293T cells. At 48 hpt, cells were lysed in RIPA buffer without SDS. An aliquot (40%) of
the clarified cell lysate was treated with RNase A (2.5 U/100 l lysate) and RNase T1 (10 U/100 l lysate) for 1 h at room temperature. Equal
amounts of lysates with or without RNase treatment were subjected to co-IP with anti-Flag or anti-HA antibody, and WB was performed with
anti-HA or anti-Flag antibody, respectively. Approximately 3% of whole-cell lysates (WCL) was also examined by WB with the antibodies shown.
Actin served as a loading control. The panel (total RNA) shows the removal of RNA (lane 3) following RNase A/T1 treatment. (B) WB to
demonstrate the interaction of PCBP1 with P. The experiment was conducted as described for panel A. The interaction with PCBP2 was used as
a positive control in this experiment. (C) Colocalization of PCBP2 and PCBP1 with VSV P protein in VSV-infected HeLa cells. HeLa cells were
transfected with plasmids carrying HA-PCBP2 (panels i to v) or HA-PCBP1 (panels vi to x), and at 48 hpt cells were infected with VSV (panels
iii to v and viii to x) or mock infected (panels i, ii, vi, and vii) for 3 h. The cells were immunostained with anti-HA monoclonal and anti-P polyclonal
antibody followed by anti-mouse Alexa Fluor 594 (red), anti-rabbit Alexa Fluor 488 (green), and 4,6-diamidino-2-phenylindole (blue) staining.
Merged images are also shown.
9462 DINH ET AL. J. VIROL.
 
distribution of both PCBP2 and PCBP1 (panels iv and ix) was
not significantly altered. However, we could detect the colo-
calization of VSV P with PCBP2 throughout the cytosol (panel
v), whereas the colocalization of VSV P with PCBP1 was ob-
served in some regions of the cytoplasm (panel x). These data
indicate that VSV infection does not significantly alter the
normal localization of PCBP2 and PCBP1 in infected cells but
that VSV P protein colocalizes with PCBP2 more so than with
PCBP1 protein.
Depletion of PCBP2 but not PCBP1 by siRNA enhances VSV
growth. The observation that PCBP2 and PCPB1 interact with
VSV P prompted us to examine the relevance of this interac-
tion for the VSV life cycle. To this end, we used specific
siRNAs to deplete PCBP2 or PCBP1 from HeLa cells. Treat-
ment of cells with siRNA for PCBP2 led to efficient depletion
of the protein in these cells, even at the lowest concentration
(0.1 nM) of siRNA used (Fig. 3A). In cells depleted of PCBP2,
VSV infection resulted in a significant increase in viral proteins
(as a function of viral gene expression) compared to the cells
treated with NT siRNA (Fig. 3B and C). PCBP2-silenced cells
exhibited more than a 3-fold increase of viral M protein, which
also correlated well with a similar increase in infectious viral
titer in the supernatant (Fig. 3D). Although we had observed
similar effects of PCBP2 depletion or overexpression on the
levels of the VSV N, P, M, and G proteins (data not shown),
only the data for the M protein have been presented here. For
PCBP1, the best depletion was achieved at a 10 to 20 nM
concentration of siRNA (Fig. 3E). Under these silencing con-
ditions, we did not observe any significant differences in viral
protein expression (Fig. 3F) or infectious virus production in
the culture supernatants (Fig. 3G). Additionally, no differences
in viral protein production or infectious virus titers were ob-
served at early (6 hpi) or late (15 hpi) times of infection (data
not shown). Overall, the results show that depletion of cellular
PCBP2 has a negative consequence on virus gene expression
and growth, whereas depletion of PCBP1 does not adversely
affect these virus-specific steps.
Overexpression of PCBP2 but not PCBP1 suppresses VSV
growth. The observation that depletion of PCBP2 resulted in
enhanced gene expression and viral growth prompted us to
examine the effects of overexpression of this protein on VSV.
HeLa cells were transiently transfected with the plasmid car-
rying HA-PCBP2 and subsequently infected with VSV. In
these cells, HA-PCBP2 could be readily detected (Fig. 4A).
When the cells were infected with VSV, viral gene expression
as assayed by detection of M protein was reduced by approx-
imately 3-fold (Fig. 4A and B). A similar reduction in viral titer
was also observed in the supernatant of these cells (Fig. 4C).
On the other hand, overexpression of HA-PCBP1 did not
result in any significant difference in viral gene expression or
infectious virus production (Fig. 4D and E). Thus, these results
together with those from knockdown experiments highlight the
antagonistic properties of cellular PCBP2 on VSV infection.
The interaction of PCBP2 with P does not disrupt interac-
tions among viral proteins. In VSV-infected cells, the P pro-
tein interacts with the other viral proteins, namely, the N and
L proteins, as well as with itself to form complexes that are
required for viral RNA synthesis (20, 32, 41). The observed
FIG. 3. Knockdown of PCBP2 but not PCBP1 enhances VSV growth. (A) Knockdown efficiency of siRNA against PCBP2. HeLa cells were
treated with siRNA targeting PCBP2 at final concentrations of 0.1, 1, 5, 10, and 20 nM or with 20 nM nontargeting (NT) siRNA. PCBP2 expression
was determined by WB at 72 hpt with anti-PCBP2 polyclonal antibody. (B) VSV infection is enhanced in PCBP2-depleted cells. HeLa cells treated
with NT siRNA or PCBP2 siRNA at 10 nM for 68 to 72 h were infected with VSV-eGFP at an MOI of 0.01 for 8 h. VSV M protein and endogenous
PCBP2 were detected by WB with anti-M monoclonal antibody and anti-PCBP2 antibody. (C) Quantitation of M protein levels (arbitrary units)
from three independent experiments, as described for panel B. The level of M expression in the NT siRNA-treated sample was set at 1. (D) VSV
titer in PCBP2-depleted cells. siRNA treatment and virus infections were performed similarly, as for panel B, and virus titers in supernatants
collected at 12 hpi were determined by plaque assay and expressed as PFU/ml. (E) Knockdown efficiency of siRNA against PCBP1. siRNA
concentrations used were similar to those for panel A. PCBP1 expression was determined by WB at 72 hpt with anti-PCBP1 polyclonal antibody.
(F) VSV infection in PCBP1-depleted cells. Cells, silencing conditions, and the MOI used were similar to those for panel B, but cells were
harvested at 3 or 5 hpi. WB was done with anti-M and anti-PCBP1 antibody. Actin served as a loading control. (G) VSV growth in PCBP1-depleted
cells. Cells, PCBP1 siRNA treatment, infection with VSV, and virus titration were similar to those described for panels B and D. Error bars
represent the standard errors of means from at least 3 independent experiments.
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decrease of virus replication in cells when PCBP2 was ectopi-
cally expressed raised the possibility that the interaction of
PCBP2 with P protein may interfere with the interactions of
the viral proteins with the P protein. To explore this possibility,
we used the stable cell line 293-NPeGFPL, which constitutively
expresses the VSV replication proteins, N, PeGFP (a fusion
protein with enhanced GFP [eGFP] inserted in frame after
amino acid 196 of VSV P protein), and the L protein and
supports efficient VSV defective interfering particle genome
replication (47). These cells were cotransfected with the plas-
mid carrying Flag-P together with increasing amounts of the
plasmid carrying HA-PCBP2. Cell extracts from these cells
were subjected to co-IP with anti-Flag antibody, and the pro-
tein species were detected by immunoblotting with various
antibodies. If the P-PCBP2 interaction abrogated or affected
the interaction of P with PeGFP or N, the amount of PeGFP
or N proteins bound and precipitated by Flag-P would be
expected to be reduced during co-IP with anti-Flag antibody.
Results showed that similar amounts of PeGFP and N protein
were immunoprecipitated by anti-Flag antibody, irrespective of
the level of HA-PCBP2 expressed in these cells (Fig. 5A). To
examine if the P-L interaction was affected by the presence of
overexpressed PCBP2, the 293-NPeGFPL cells were trans-
fected with increasing amounts of the plasmid carrying HA-
PCBP2, and the cell extracts were used for immunoprecipita-
tion with anti-L antibody and immunoblotted with the
antibodies shown. The amount of PeGFP pulled down by the
antibody was not affected by the presence of overexpressed
PCBP2 (Fig. 5B). These results indicate that overexpression of
PCBP2 does not affect the interaction of PeGFP with L pro-
tein. It is worth mentioning here that the PeGFP fusion protein
interacts with PCBP2 to a similar extent as the Flag-P protein
(data not shown). Taken together, these results demonstrate
that the presence of HA-PCBP2 and its interaction with VSV
P does not interfere with the interactions among the viral
proteins to form functional complexes for viral gene expres-
sion.
PCBP2 does not induce degradation of P protein. PCBP2
has been shown to interact with MAVS and induce its degra-
dation via ubiquitination by E3 ubiquitin ligase AIP4 through
proteasome pathway (67). It is then possible that inhibition of
virus growth by PCBP2 could be in part due to degradation of
the P in infected cells. Interestingly, by MS analysis, we de-
tected ubiquitin in the Flag-P pull-down sample (Fig. 1), indi-
cating that P may be ubiquitinated in cells. Examination of
ubiquitination of P protein in cells transfected with plasmids
carrying HA-tagged ubiquitin (HA-Ub) and P proteins re-
vealed that the P protein was indeed ubiquitinated (Fig. 6A).
In cells infected with VSV, the P protein was also found to be
ubiquitinated (Fig. 6B). Since protein degradation by the pro-
teasome pathway is regulated by ubiquitination of protein, we
examined whether the P protein is degraded by the proteasome
pathway. When P protein-expressing cells were treated with
the proteasomal inhibitor MG132, the level of P protein in-
creased significantly compared to the cells not treated with the
inhibitor (Fig. 6C). These observations indicate that VSV P
protein is ubiquitinated and its degradation is dependent on
the proteasome pathway.
To examine if VSV P protein degradation is regulated by
PCBP2, we determined the levels of P protein in cells cotrans-
fected with a fixed amount of the plasmid carrying the P pro-
tein and increasing amounts of the plasmid carying HA-
PCBP2. Results showed no observable differences in the level
of P protein in cells expressing increasing amounts of HA-
FIG. 4. Overexpression of PCBP2 but not PCBP1 suppresses VSV growth. (A) VSV infection is suppressed in PCBP2-overexpressing cells.
HeLa cells transfected with 1.5 g of EV- or HA-PCBP2-carrying plasmid for 48 h were infected with VSV at an MOI of 0.01 for 8 h, and cell
lysates were analyzed by WB using anti-M or anti-HA antibodies. Actin served as a loading control. (B) Quantitative determination of levels of
M (arbitrary units) from three independent experiments as described for panel A. The level of M expression in EV-transfected cells was set at 1.
(C) Reduced VSV growth in PCBP2-overexpressing cells. Transfection and infection conditions were as described for panel A, but the titer of virus
in the supernatant collected at 12 hpi was determined. (D) VSV infection in PCBP1-overexpressing cells. HeLa cells transfected with EV or
HA-PCBP1 plasmid were infected with VSV at an MOI of 0.01 for 3 or 5 h, and the cell lysates were analyzed by WB using anti-M or anti-HA
antibodies. Actin served as a loading control. (E) VSV growth in PCBP1-overexpressing cells. Transfection and infection conditions were as
described for panel C. Virus titers in the supernatants collected at 12 hpi were determined. Error bars represent the standard errors of means from
3 independent experiments.
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PCBP2 (Fig. 6D), indicating that PCBP2 has no effect on P
protein degradation. Since PCBP2 is known to induce MAVS
degradation to prevent uncontrolled interferon (IFN) produc-
tion (67), we then asked if in the context of activated IFN
production, PCBP2 might function to reduce the P protein
level by inducing its degradation, which otherwise might not be
observed in the absence of IFN induction. To address this
possibility, we expressed HA-PCBP2 in the 293-NPeGFPL cell
line and then mock infected cells or infected cells with DI
particles of VSV. Infection of these cells with DI particles
resulted in stimulation of IFN production by up to 90-fold (Fig.
6E), consistent with our previous report (47). In the presence
of PCBP2, the activation of the IFN pathway is partially re-
pressed (Fig. 6E), as has been documented before (67). Nev-
ertheless, the level of PeGFP protein was similar in cells with
or without HA-PCBP2 expression (Fig. 6F). Taken together,
the results from these experiments suggest that interaction of
PCBP2 with VSV P protein does not lead to degradation of
this viral protein.
Although our previous experiments indicated that VSV P
protein is not a direct target of the PCBP2 degradation path-
way, it is possible that PCBP2’s restrictive effect on viral growth
is mediated through proteasomal degradation of other cellular
proteins. To investigate if a functional proteasome is required
for PCBP2-mediated suppression of viral growth, we used
MG132 to block the proteasomal pathway in cells treated with
NT siRNA or PCBP2 siRNA (dimethyl sulfoxide [DMSO]
treatment was used as the vehicle control). Under these con-
ditions, we still observed a 2.5-fold increase of virus titer in
PCBP2-silenced cells compared to NT siRNA-transfected cells
in MG132-treated cells (Fig. 6G, right panel). It should be
noted that treatment of cells with MG132 resulted in signifi-
cant inhibition of VSV growth (Fig. 6G, right panel) compared
to DMSO treatment (Fig. 6G, left panel), consistent with a
previously reported inhibitory effect of MG132 on VSV growth
(33). A similar increase in titers was also observed with DMSO
treatment (Fig. 6G, left panel). This suggests that the inhibi-
tory effect of PCBP2 on VSV growth is independent of the
proteasome pathway.
PCBP2 exerts its inhibitory effect on VSV growth at the level
of viral gene expression. The observed increases in viral pro-
tein expression and virus titer following PCBP2 silencing do
not indicate whether this cellular protein exerts its inhibitory
effect on VSV replication at the viral entry and uncoating step
or at the gene expression step. To address this, we prepared
viral RNPs from purified virions and transfected them directly
FIG. 5. The P-PCBP2 interaction does not disrupt the formation of viral protein complexes. (A) Formation of N-P and P-P complexes in the
presence of PCBP2. The NPeGFPL stable cell line (clone 206) along with a stable 293 cell control (293 Ctr) were transfected with 2 g
Flag-P-carrying plasmid along with EV or plasmid carrying HA-PCBP2 at increasing concentration of 0.5 g, 1 g, and 2 g (wedge). At 48 hpt,
cell lysates were used for co-IP with anti-Flag antibody followed by WB with the indicated antibodies (on the left). The detected proteins are shown
on the right. WB results with whole-cell lysates (WCL) corresponding to 3% of total extract with the indicated antibodies (bottom panels) show
the amount of various proteins. (B) Formation of the P-L complex in the presence of HA-PCBP2. NPeGFPL stable cells were transfected with
increasing amounts of HA-PCBP2 carrying plasmid at 2 g, 5 g, and 10 g (wedge). At 48 hpt, anti-L polyclonal antibody was used in co-IP of
cell lysates, and subsequently the samples were analyzed by WB with the indicated antibodies. Actin served as a loading control in these
experiments. WB results with whole-cell lysates corresponding to 3% of total extract with the indicated antibodies (bottom panels) show the
amounts of various proteins.
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into cells depleted of PCBP2 (by siRNA) or overexpressing
PCBP2 (by prior transfection with the HA-PCBP2-carrying
plasmid). The viral RNP from purified virions can initiate viral
gene expression upon introduction into naïve cells by transfec-
tion (unpublished data). If the inhibitory effect of PCBP2 were
at the virus entry and uncoating step, bypassing this step
through transfection of RNP into the cell would result in viral
gene expression that is independent of the presence or absence of
PCBP2. Results from such experiments showed that the viral M
protein level (as a function of viral gene expression) increased
significantly following siRNA-mediated depletion of PCBP2 (Fig.
7A, left panels) and was reduced significantly when PCBP2 was
overexpressed (Fig. 7A, right panels). Furthermore, the level of
enhancement (in PCBP2-depleted cells) or reduction (in PCBP2-
overexpressing cells) of viral gene expression was similar whether
RNP transfection or virus infection was used (Fig. 3 and 4).
Therefore, the results indicate that PCBP2 inhibits VSV infection
at a step after virus entry and uncoating.
FIG. 6. PCBP2 does not induce the degradation of viral proteins. (A) Ubiquitination of VSV P protein. Cell lysates at 48 hpt from 293T cells
transfected with the indicated combination of 2 g each of EV, VSV P, or HA-ubiquitin-expressing plasmid was used for co-IP with anti-P or
anti-HA antibodies, followed by WB with anti-HA or anti-P antibody, respectively. WB results with WCL corresponding to 3% of total extract with
various antibodies are also shown at the bottom. Actin served as a loading control in these experiments. Molecular mass markers in kilodaltons
are shown on the left. (B) Ubiquitination of P protein in VSV-infected 293T cells. Cells were infected with VSVeGFP at an MOI of 5 for 5 h.
Whole-cell lysates were used for IP with antiubiquitin antibody followed by WB with anti-P antibody. Molecular mass markers in kilodaltons are
shown on the left. (C) Proteasome-mediated degradation of VSV P protein. VSV P-carrying plasmid (2 g) was transfected into 293T cells, and
at 24 hpt the transfected cells were treated with DMSO or MG132 at 30 M for 12 h. The amount of P protein was determined by WB with anti-P
polyclonal antibody. (D) P protein level when coexpressed with PCBP2. Cells were transfected with 0.5 g VSV P-carrying plasmid along with
increasing amounts (0.1 g, 0.25 g, and 0.5 g) of HA-PCBP2 plasmid. At 48 hpt, cell lysates were prepared for WB with anti-P and anti-HA
antibodies. (E) Relative luciferase activity in a stable cell line supporting DI particle RNA replication and overexpressing PCBP2. NPeGFPL stable
cells were transfected with 1 g EV or plasmid carrying HA-PCBP2 along with 10 ng pTKRL and 0.4 g pISG56-luc. At 28 hpt, the cells were
mock infected (lanes 1 and 3) or infected with DI particles (lanes 2 and 4). At 16 hpi, cells were lysed and assayed using the Dual-Luciferase assay
kit (Promega). Luciferase activity (lanes 2 and 4) was expressed as the relative fold induction over the level in uninfected control cells (lanes 1 and
3) after normalization with respect to Renilla luciferase activity. (F) PeGFP protein levels in a stable cell line supporting DI replication and
expressing PCBP2. NPeGFPL stable cells transfected with EV or plasmid carrying HA-PCBP2 were mock infected or infected with DI particles
at 28 hpt and harvested at 16 hpi for analysis by SDS-PAGE and WB with anti-GFP or anti-HA antibodies. Actin was the loading control for WCL.
(G) VSV titers in cells with PCBP2 depleted and the proteasome pathway inhibited. HeLa cells were treated with siRNA as for Fig. 3B and infected
with VSV at an MOI of 0.01. One hour after infection, cells were incubated in complete medium containing DMSO (left panel) or 2 M
proteasome inhibitor MG132 (right panel). The supernatants were collected at 16 h postinfection for a plaque assay. Error bars represent the
standard errors of means from 2 independent experiments.
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To ascertain if PCBP2 affects VSV growth at the level of
virus budding, we utilized VSV-PeGFP-G virus, which lacks
the G coding sequence in the viral genome. Infectious G
viruses can be generated from transfected cells by comple-
menting with G protein (65). Since VSV G protein is required
for virus budding and infectivity (8, 43), the G virus is defec-
tive in producing infectious progeny virions and undergoes
only a single round of infection. Using VSV-PeGFP-G, we
observed that the level of viral gene expression was increased
by approximately 3-fold when the cells were depleted of
PCBP2 and decreased similarly when PCBP2 was overex-
pressed (Fig. 7B). More importantly, the level of increase or
decrease in viral gene expression was similar whether the bud-
ding-competent VSV-PeGFP or budding-incompetent VSV-
PeGFP-G virus was used in these studies (Fig. 7C). Taken
together, these studies suggest that PCBP2 primarily inhibits
VSV gene expression without adversely affecting the viral entry
and uncoating or budding steps.
To further determine if PCBP2 affects VSV RNA synthesis
at the level of transcription, replication, or both, we examined
the effects of depletion or overexpression of PCBP2 on viral
primary transcription. Immediately after uncoating in the cy-
toplasm, the input RNP undergoes primary transcription to
produce viral mRNAs, which are then translated to produce
viral proteins that are required for subsequent replication and
secondary transcription. In the presence of inhibitors of pro-
tein synthesis, such as cycloheximide, viral RNA synthesis will
be limited to primary transcription. We therefore conducted an
experiment in which the cells were treated with PCBP2 siRNA
and then infected with VSV in the presence of cycloheximide.
VSV mRNAs resulting from primary transcription alone were
quantitated by semiquantitative RT-PCR. Results showed that
synthesis of VSV N mRNA was increased greater than 10-fold
when PCBP2 was depleted, whereas in cells overexpressing
PCBP2, N mRNA synthesis was reduced by approximately
3-fold (Fig. 8A). Examination of VSV P mRNA by semiquan-
titative RT-PCR showed that the levels of this mRNA were
also affected similarly (data not shown), indicating that the
effect of PCBP2 is not specific to viral N mRNA transcription.
A similar effect on the overall level of transcription in the
absence of cycloheximide was observed (data not shown), in-
dicating that PCBP2 inhibits viral mRNA transcription. Exam-
ination of viral antigenome (replication product) levels in the
absence of cycloheximide revealed that depletion of PCBP2
led to increased genome replication, whereas its overexpres-
sion resulted in inhibition of replication (Fig. 8B). These re-
sults suggest that PCBP2 negatively affects VSV mRNA syn-
thesis and genome replication.
Although overall growth and gene expression were not in-
fluenced by PCBP1 (Fig. 3 and 4), considering its overlapping
functions with PCBP2, we examined if PCBP1 might affect
certain steps in VSV gene expression. Interestingly, using the
same experimental settings as above, we found that cells de-
pleted of PCBP1 could support more viral primary transcrip-
tion (
8-fold) and, conversely, that overexpression of PCBP1
resulted in a greater-than-2-fold reduction of primary tran-
scription (Fig. 8C). However, the inhibitory effect of PCBP1 on
viral genome replication was not observed (Fig. 8D). Taken
together, the results indicate that PCBP1 exerts its inhibitory
effect at the primary transcription step.
DISCUSSION
The P protein of VSV is the noncatalytic subunit of the viral
RdRp. Its phosphorylation status and interactions with the
other viral proteins involved in viral genome transcription and
replication regulate its activity in these processes (20, 35).
Furthermore, P has been shown to play a role in assembly of
infectious virus particles (19). Since the P protein regulates
multiple functions in the life cycle of VSV, we reasoned that it
must interact with many host cell proteins. Currently, little is
known about the host cell proteins that interact and modulate
FIG. 7. The antagonistic effect of PCBP2 on VSV infection is not dependent on virus entry and uncoating or virus budding. (A and B) HeLa
cells were transfected with 10 nM siRNA for NT or PCBP2 for 72 h (A and B, left panels) or transfected with 1.5 g of EV or HA-PCBP2-carrying
plasmids for 48 h (A and B, right panels). Cells were then supertransfected for 12 h with nucleocapsids prepared from VSV-PeGFP (A) or infected
with VSV-PeGFP-G at an MOI of 0.2 for 8 h (B). Equal amounts of cell lysates from both experiments were analyzed by SDS-PAGE and WB
with anti-PCBP2, anti-M, or anti-HA antibodies as indicated. Actin was the loading control. M proteins levels were determined by densitometric
quantitation. M protein levels (histograms) were set at 1 in NT siRNA-treated cells as well as in EV-transfected cells. (C) Levels of M protein in
cells treated with siRNA or transfected with the indicated plasmids and then infected with VSV-PeGFP or VSV-PeGFP-G virus. Error bars
represent the standard errors of means from 2 independent experiments.
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functions of the P proteins of VSV. One early report suggested
that the P protein associates with c-src (6); however, the func-
tional significance of this association is unclear. Interaction of
the P protein of rabies virus with dynein light chain LC8 has
been shown to be required for its activity in viral genome
transcription and replication (52, 56). The P proteins of rabies
virus and Borna disease virus have also been shown to antag-
onize the IFN response (13, 50, 60). The Borna disease virus P
protein interacts with GABARAP, and this interaction results
in relocalization of GABARAP from the cytoplasm to nucleus
(50). The nucleocapsid proteins of negative-strand RNA vi-
ruses also interact with host proteins and regulate virus RNA
synthesis. Cyclophilin A binds to the N protein and is a re-
quired factor for replication of VSVNJ but not VSVI (10).
Recently, peroxiredoxin 1 was identified as a binding partner of
the nucleocapsid protein of measles virus and was found to be
required for its replication and transcription (63). Hantavirus
nucleocapsid protein binds to a ribosomal protein, RPS19, and
mediates preferential translation of viral mRNA (14). Thus,
several viral replication proteins appear to interact with cellu-
lar proteins to modulate a variety of functions required for
successful replication of the virus in the host.
In an attempt to identify the cellular proteins that interact
with VSV P protein and understand the functional importance
of these interactions, we employed an IP assay to pull down
host factors interacting with the VSV P protein and subse-
quently used MS analysis to identify these proteins. Among the
many cellular proteins identified, we focused our studies on
PCBP2 and PCBP1, two members of a family of hnRNPs,
which are known to regulate transcription, translation, and
mRNA stability in cells (46). In this study, we demonstrated
that PCBP2 and PCBP1 function as negative regulators of
FIG. 8. PCBP2 and PCBP1 restrict VSV at the primary transcription step. HEK293 cells were treated with 10 nM siRNA for NT, PCBP2, or
PCBP1 for 68 to 72 h or transfected with 2 g of EV-, HA-PCBP2-, or HA-PCBP1-carrying plasmids for 48 h. (A and C) VSV primary transcription
assays. Cells were treated with cycloheximide for 1 h prior to infection with VSV-eGFP at an MOI of 50 for 2.5 h. Total RNA was extracted from
cells by using TRIzol. Subsequently, cDNA was synthesized with oligo(dT) primer followed by PCR with specific primers binding to VSV N mRNA
or primers for the mRNA of cellular ribosomal protein L32 as an internal control. The level of N mRNA was normalized to 1 in NT siRNA-treated
cells or in EV-transfected cells. “No cDNA,” PCR amplification performed without cDNA in the reaction mixture. (B and D) VSV replication
(antigenome) assays. Cells were infected with VSV-eGFP at an MOI of 0.2 for 3.5 h, followed by total RNA extraction and semiquantitative
RT-PCR using specific primers complementary to P and M coding regions to detect VSV antigenomic RNA. Ribosomal protein L32 was used as
an internal control. Error bars represent the standard errors of means from 3 independent experiments. RT-PCR was performed for 25 cycles with
samples from PCBP depletion experiments or 35 cycles with samples from protein-overexpressing cells.
9468 DINH ET AL. J. VIROL.
VSV infection in human cell types, including HeLa and
HEK293. Further examination revealed that these two pro-
teins specifically inhibit viral gene expression.
Although PCBP2 and PCBP1 are two isoforms of the same
family of proteins with nearly 90% sequence identity (58), the
inhibitory effects of PCBP2 on VSV growth and viral gene
expression were significantly more pronounced than those of
PCBP1 (Fig. 3 and 4). The reasons for this are unknown at this
time but could be in part due to the fact that the amount of
PCBP1 is lower in the cytoplasm, where VSV replicates exclu-
sively. It is also possible that the inherent differences in their
inhibitory activities on VSV could be due to their associations
with other cellular interacting partners. Members of the PCBP
family are known to form functional multimers with other
cellular proteins for their shuttling between the nucleus and
the cytoplasm as well as for their functions. PCBP2 is known to
interact with at least hnRNP K, I, and L (37). Furthermore,
PCBP2 interacts with myotonic dystrophy type 2 protein ZNF9
in regulating ornithine decarboxylase expression (30) and as-
sociates with the nucleo-cytoplasmic SR protein (SRp20) to
modulate poliovirus genome translation (5), whereas PCBP1
acts together with hnRNP A2 in negatively controlling the
expression of mRNA containing A2 response elements (38).
Whether the associations of different cellular proteins with
PCBP2 and PCBP1 are responsible for the observed differ-
ences in inhibition of VSV growth and gene expression is
unknown, and further studies along these lines may help us
understand more about the inhibitory effects of these two pro-
teins on VSV. Additionally, PCBP1 and PCBP2 form func-
tional homo- and heterodimers in supporting translation and
replication of poliovirus genome RNA. It has been shown that
PCBP1 can rescue poliovirus replication when PCBP2 is de-
pleted in the cell (29, 62), demonstrating a functional cooper-
ation between these two proteins in poliovirus replication.
Such cooperation does not seem to exist in inhibiting or en-
hancing VSV replication, as overexpression or depletion of
both proteins simultaneously did not inhibit or enhance VSV
growth significantly (data not shown) compared to the individ-
ual proteins.
To understand how PCBP2 is involved in inhibiting VSV
growth and viral gene expression, we examined whether
PCBP2 interfered with the formation of viral replication pro-
tein complexes, which are required for transcription and rep-
lication of the VSV genome. However, our studies showed that
the interaction of PCBP2 with VSV P protein did not interfere
with the formation of complexes of N-P or L-P or the homo-
oligomerization of P-P protein. A recent study showed that
PCBP2 interacts with MAVS and mediates its degradation
through the proteasome pathway via ubiquitination by the E3
ubiquitin ligase AIP4 (67). Since the proteasome pathway is
also involved in inhibition of VSV (33), we examined whether
degradation of P through the proteasome pathway by ubiquiti-
nation might account for the inhibition of VSV by PCBP2.
Although the studies reported here successfully demonstrated
for the first time ubiquitination of the VSV P protein and its
degradation through the proteasome pathway, the results also
sugges that PCBP2 does not directly target the P protein for
degradation. So, the inhibition mediated by PCBP2 is indepen-
dent of the proteasome pathway. Therefore, the exact mecha-
nism by which PCBP2 exerts its inhibitory effect remains to be
elucidated. Further studies on PCBP2-interacting proteins may
reveal how PCBP2 inhibits VSV growth and gene expression.
The effects of PCBP2 and PCBP1 on replication of other
viral pathogens have been found to be variable. For example,
PCBP2 binds the 5-untranslated region (UTR) and enhances
translation of the internal ribosome entry site (IRES) contain-
ing mRNA of several positive-strand RNA viruses, such as
poliovirus, enterovirus, hepatitis A virus, and coxsakievirus (24,
31, 45, 55). On the other hand, its binding to the 5-UTR of
HCV has no effect on translation of HCV IRES-containing
genomic RNA (28). Additionally, PCBP1 but not PCBP2 me-
diated a strong inhibition of gene expression steps in HIV-1
infection (66). While a role for PCBP2 and PCBP1 has not
been reported for replication of any of the negative-strand
RNA viruses yet, our findings that PCBP2 and PCBP1 are
antagonists for VSV infection provide the first example of the
involvement of these proteins in gene expression of this class of
RNA viruses. The results underscore the complexity of PCBP
regulatory functions in virus-infected cells. PCBP2 is induced
following virus-mediated IFN induction. Although it down-
regulates the IFN response stimulated by viral pathogens (67),
in this study we showed that it suppresses VSV growth by
targeting viral gene expression. Other interferon-induced pro-
teins, such as IFITM3, tetherin, and Ars2, have been shown
recently to inhibit VSV replication at different stages of infec-
tion. While Ars2 (54) restricts VSV replication at the level of
viral RNA synthesis, IFITM3 targets an early event after en-
docytosis and before primary transcription, and tetherin blocks
virion budding from infected cells (64). Thus, the host cells
employ multiple and redundant mechanisms to restrict repli-
cation of an invading pathogen. In concordance with a previous
report (67), we also observed an increase of PCBP2 protein
level in VSV-infected cells (data not shown). Thus, PCBP2
seems to restrict VSV replication at the level of primary and
secondary transcription as well as genome replication, whereas
the role of PCBP1 in VSV replication appears to be more
restricted. While the viral genome replication was not ad-
versely affected by PCBP1, only the primary transcription was
affected negatively by this protein. Additional studies will be
needed to understand further the role of PCBP1 in inhibiting
VSV primary transcription. Moreover, oligoadenylate synthe-
tase (OAS) and RNase L, which are also induced by IFN (57),
are involved in blocking VSV protein synthesis and thus virus
replication (1, 4). Since PCBP2 mRNA is the activator for
OAS (44), it would be interesting to examine the relationship
between PCBP2, OAS, and RNase L in restricting replication
of VSV and other viruses.
The findings reported here add to the ever-increasing list of
functions reported for PCBP2 and PCBP1. We have demon-
strated the effects of PCBP2 and PCBP1 at the level of viral
gene expression during VSV infection. It is possible that
PCBP2 and PCBP1 affect the viral mRNA transcription pro-
cess itself, or mRNA stability, or both. PCBP2 and PCBP1
have been implicated in negatively regulating the stability of
p21 mRNA (61). Furthermore, both PCBP1 and PCBP2 have
been shown to be components of stress granules (SG) and
processing bodies (P-bodies), and thus they have been pro-
posed to participate in targeting newly synthesized mRNA to
P-bodies for storage and/or degradation (26, 27). It has been
reported that siRNA-mediated depletion of TIA-1, a compo-
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nent of SG, results in increased replication of VSV (40). Our
preliminary data suggest that VSV induces SG formation in
infected cells (P.X.D. and A.K.P., unpublished data). It is
possible that PCBP2 and PCBP1 directly interact with viral
RNA species (like the genome, antigenome, mRNA, and
leader and trailer RNAs) to sequester them in SG, thereby
inhibiting viral gene expression, or that their binding impedes
the accessibility of the P-L complex to viral RNAs and thus
reduces viral gene expression.
In summary, our results demonstrate the antagonistic effects
of PCBP2 and PCBP1 on VSV infection in cell culture systems.
The inhibitory effects were shown to be at the level of viral
gene expression. The molecular mechanism(s) by which
PCBP1 and PCBP2 exert their inhibitory effects on VSV RNA
synthesis are under investigation.
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